---
title: "Centros Não Identificados"
output: 
  md_document:
    variant: gfm  # GitHub-flavored Markdown (for better rendering on GitHub)
    preserve_yaml: true  # Keep YAML metadata in the output
params:
  db: ''
---

Você encontrará aqui a lista de centros ainda não identificados, dividos
por estudo. Caso você reconheça algum centro por meio do estudo em
andamento e da descrição, **clique no centro** que você será
redirecionado para um formulário para identificação dele.

*NOTA*: Para facilitar a identificação dos centros, para cada estudo em
que há um centro não identificado, também disponibilizamos os centros
identificados para que a pessoa, ao identificar o centro, verificar se
esse centro já não existe na própria base de dados.

Obrigado por colaborar!

**NCT05556096**: Estudo multicêntrico de Fase 3 que avalia a segurança e
eficácia do ALXN1720 em adultos com miastenia gravis generalizada e
autoanticorpos contra AChR.

Patrocinador do Estudo: Alexion Pharmaceuticals, Inc.

- <span style="color: darkgray">BA: 41253-190, Salvador</span>
- [**CNI**: Research Site 14051-140, Ribeirão Preto,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05556096&location_id=RESEARCHSITERIBEIRAOPRETO14051140BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2014051-140%2C%20Ribeir%C3%A3o%20Preto%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 0438-002, São Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05556096&location_id=RESEARCHSITESAOPAULO0438002BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%200438-002%2C%20S%C3%A3o%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">RS: 90110-270, Porto Alegre</span>
- <span style="color: darkgray">SC: 89202-030, Joinville</span>
- <span style="color: darkgray">SP: 15090-000, São José do Rio
  Preto</span>
- <span style="color: darkgray">SP: 05403-010, São Paulo</span>
- <span style="color: darkgray">SP: 14784-400, Barretos</span>

**NCT03937154**: (PROCLAIM) Estudo de fase 3, randomizado, controlado
por placebo e duplo-cego, avaliando romiplostim para tratar
trombocitopenia induzida por quimioterapia em pacientes com câncer de
pulmão, ovário ou mama.

Patrocinador do Estudo: Amgen

- [**CNI**: Loema Instituto de Pesquisa Clinica e Consultores Ltda
  13010-001, Campinas, São
  Paulo](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT03937154&location_id=LOEMAINSTITUTODEPESQUISACLINICAECONSULTORESLTDACAMPINASSAOPAULO13010001BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Loema%20Instituto%20de%20Pesquisa%20Clinica%20e%20Consultores%20Ltda%2013010-001%2C%20Campinas%2C%20S%C3%A3o%20Paulo&form_type=Identificar%20Centro)
- <span style="color: darkgray">PI: 64049-200, Teresina</span>
- <span style="color: darkgray">PR: 82305-100, Curitiba</span>
- <span style="color: darkgray">RN: 59062-000, Natal</span>
- <span style="color: darkgray">RS: 90035-007, Porto Alegre</span>
- <span style="color: darkgray">RS: 95020-371, Caxias do Sul</span>
- <span style="color: darkgray">SC: 88301-220, Itajaí</span>
- <span style="color: darkgray">SP: 08270-070, São Paulo</span>
- <span style="color: darkgray">SP: 15090-000, São José do Rio
  Preto</span>
- <span style="color: darkgray">SP: 14784-400, Barretos</span>
- <span style="color: darkgray">SP: 01317-000, São Paulo</span>

**NCT02960022**: Estudo de extensão de fase 2 aberto coletando dados de
segurança a longo prazo para pacientes com câncer de próstata
beneficiando-se de Enzalutamida após participação em estudo clínico
anterior.

Patrocinador do Estudo: Astellas Pharma Global Development, Inc.

- <span style="color: darkgray">BA: 41253-190, Salvador</span>
- [**CNI**: Site BR55008 - , Campinas,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT02960022&location_id=SITEBR55008CAMPINASBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Site%20BR55008%20%20-%20%2C%20Campinas%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">RS: 98700-000, Ijuí</span>
- <span style="color: darkgray">RS: 90610-000, Porto Alegre</span>
- <span style="color: darkgray">RS: 90430-090, Porto Alegre</span>
- <span style="color: darkgray">SP: 09060-650, Santo André</span>
- <span style="color: darkgray">SP: 17210-070, Jaú</span>

**NCT04960709**: (VOLGA) Estudo randomizado de fase III que avalia a
eficácia e segurança de Durvalumab com Tremelimumab e Enfortumab Vedotin
ou Durvalumab com Enfortumab Vedotin em pacientes com câncer de bexiga
inelegíveis para cisplatina.

Patrocinador do Estudo: AstraZeneca

- <span style="color: darkgray">CE: 60135-237, Fortaleza</span>
- [**CNI**: Research Site 03162-065, Săo Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT04960709&location_id=RESEARCHSITESAOPAULO03162065BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2003162-065%2C%20S%C4%83o%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">MG: 38408-150, Uberlândia</span>
- <span style="color: darkgray">PR: 81520-060, Curitiba</span>
- <span style="color: darkgray">RJ: 22250-905, Rio de Janeiro</span>
- <span style="color: darkgray">RS: 90035-007, Porto Alegre</span>
- <span style="color: darkgray">RS: 91350-200, Porto Alegre</span>
- <span style="color: darkgray">RS: 90035-007, Porto Alegre</span>
- <span style="color: darkgray">RS: 97015-450, Santa Maria</span>
- <span style="color: darkgray">RS: 90610-000, Porto Alegre</span>
- <span style="color: darkgray">SP: 14784-400, Barretos</span>
- <span style="color: darkgray">SP: 01246-000, São Paulo</span>
- <span style="color: darkgray">SP: 01323-020, São Paulo</span>
- <span style="color: darkgray">SP: 09060-650, Santo André</span>

**NCT05043090**: (SAMETA) Estudo de Fase III comparando savolitinibe
mais durvalumabe versus sunitinibe e monoterapia com durvalumabe em
carcinoma de células renais papilar MET-driven, irressecável, localmente
avançado ou metastático.

Patrocinador do Estudo: AstraZeneca

- <span style="color: darkgray">BA: 40050-410, Salvador</span>
- <span style="color: darkgray">CE: 60135-237, Fortaleza</span>
- [**CNI**: Research Site 30120-320, Belo Horizonte,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05043090&location_id=RESEARCHSITEBELOHORIZONTE30120320BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2030120-320%2C%20Belo%20Horizonte%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 01327-001, Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05043090&location_id=RESEARCHSITESAOPAULO01327001BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2001327-001%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">DF: 70200-730, Brasília</span>
- <span style="color: darkgray">ES: 29308-020, Cachoeiro de
  Itapemirim</span>
- <span style="color: darkgray">ES: 29043-260, Vitória</span>
- <span style="color: darkgray">PR: 81520-060, Curitiba</span>
- <span style="color: darkgray">RJ: 22250-905, Rio de Janeiro</span>
- <span style="color: darkgray">RN: 59062-000, Natal</span>
- <span style="color: darkgray">RS: 90110-270, Porto Alegre</span>
- <span style="color: darkgray">RS: 90020-090, Porto Alegre</span>
- <span style="color: darkgray">RS: 90610-000, Porto Alegre</span>
- <span style="color: darkgray">RS: 96020-080, Pelotas</span>
- <span style="color: darkgray">SC: 88020-210, Florianópolis</span>
- <span style="color: darkgray">SC: 88811-010, Criciúma</span>
- <span style="color: darkgray">SP: 15090-000, São José do Rio
  Preto</span>
- <span style="color: darkgray">SP: 01246-000, São Paulo</span>
- <span style="color: darkgray">SP: 05652-900, São Paulo</span>

**NCT05048797**: (DESTINY-Lung04) Estudo de fase 3 comparando
Trastuzumab Deruxtecan ao tratamento padrão para tratamento de primeira
linha em pacientes com NSCLC com mutações HER2 Exon 19 ou 20.

Patrocinador do Estudo: AstraZeneca

- <span style="color: darkgray">BA: 40170-110, Salvador</span>
- [**CNI**: Research Site 01327-001, Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05048797&location_id=RESEARCHSITESAOPAULO01327001BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2001327-001%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">DF: 70200-730, Brasília</span>
- <span style="color: darkgray">MG: 38408-150, Uberlândia</span>
- <span style="color: darkgray">RN: 59062-000, Natal</span>
- <span style="color: darkgray">SC: 88034-000, Florianópolis</span>
- <span style="color: darkgray">SC: 89010-340, Blumenau</span>
- <span style="color: darkgray">SP: 14784-400, Barretos</span>
- <span style="color: darkgray">SP: 01321-001, São Paulo</span>

**NCT05211895**: (PACIFIC-8) Estudo fase III randomizado, duplo-cego de
durvalumab mais domvanalimab vs. placebo em adultos com NSCLC
irressecável estágio III após quimiorradiação à base de platina.

Patrocinador do Estudo: AstraZeneca

- [**CNI**: Research Site 20231-050, Rio de Janeiro,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05211895&location_id=RESEARCHSITERIODEJANEIRO20231050BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2020231-050%2C%20Rio%20de%20Janeiro%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">PR: 86015-520, Londrina</span>
- <span style="color: darkgray">RO: 76834-899, Porto Velho</span>
- <span style="color: darkgray">SP: 12030-200, Taubaté</span>
- <span style="color: darkgray">SP: 01221-010, São Paulo</span>
- <span style="color: darkgray">SP: 09060-650, Santo André</span>
- <span style="color: darkgray">SP: 01310-000, São Paulo</span>
- <span style="color: darkgray">SP: 04556-100, São Paulo</span>
- <span style="color: darkgray">SP: 01236-030, São Paulo</span>

**NCT05221840**: (PACIFIC-9) Estudo de fase III, duplo-cego, avaliando
durvalumabe com oleclumabe ou monalizumabe em adultos com NSCLC
irressecável estágio III após quimiorradiação à base de platina.

Patrocinador do Estudo: AstraZeneca

- <span style="color: darkgray">CE: 60335-480, Fortaleza</span>
- [**CNI**: Research Site 30380-090, Belo Horizonte,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05221840&location_id=RESEARCHSITEBELOHORIZONTE30380090BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2030380-090%2C%20Belo%20Horizonte%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">ES: 29043-260, Vitória</span>
- <span style="color: darkgray">MG: 38408-150, Uberlândia</span>
- <span style="color: darkgray">PE: 52010-075, Recife</span>
- <span style="color: darkgray">RN: 59062-000, Natal</span>
- <span style="color: darkgray">RS: 90610-000, Porto Alegre</span>
- <span style="color: darkgray">RS: 91350-200, Porto Alegre</span>
- <span style="color: darkgray">SC: 88034-000, Florianópolis</span>
- <span style="color: darkgray">SP: 01323-020, São Paulo</span>
- <span style="color: darkgray">SP: 14784-400, Barretos</span>
- <span style="color: darkgray">SP: 17210-070, Jaú</span>

**NCT05261399**: (SAFFRON) Estudo de Fase III comparando savolitinib
mais osimertinib à quimioterapia de platina em pacientes com NSCLC
mutado por EGFR e superexpressão de MET após osimertinib.

Patrocinador do Estudo: AstraZeneca

- <span style="color: darkgray">BA: 41253-190, Salvador</span>
- [**CNI**: Research Site 20231-050, Rio De Janeiro,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05261399&location_id=RESEARCHSITERIODEJANEIRO20231050BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2020231-050%2C%20Rio%20De%20Janeiro%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 90540-140, Porto Alegre,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05261399&location_id=RESEARCHSITEPORTOALEGRE90540140BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2090540-140%2C%20Porto%20Alegre%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 41950-610, Salvador,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05261399&location_id=RESEARCHSITESALVADOR41950610BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2041950-610%2C%20Salvador%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">DF: 70390-140, Brasília</span>
- <span style="color: darkgray">ES: 29043-260, Vitória</span>
- <span style="color: darkgray">ES: 29308-020, Cachoeiro de
  Itapemirim</span>
- <span style="color: darkgray">MG: 35162-761, Ipatinga</span>
- <span style="color: darkgray">MG: 30110-022, Belo Horizonte</span>
- <span style="color: darkgray">PR: 80810-050, Curitiba</span>
- <span style="color: darkgray">RJ: 22793-080, Rio de Janeiro</span>
- <span style="color: darkgray">RS: 90050-170, Porto Alegre</span>
- <span style="color: darkgray">RS: 90035-903, Porto Alegre</span>
- <span style="color: darkgray">RS: 98700-000, Ijuí</span>
- <span style="color: darkgray">SP: 04014-002, São Paulo</span>
- <span style="color: darkgray">SP: 04538-132, São Paulo</span>
- <span style="color: darkgray">SP: 04556-100, São Paulo</span>

**NCT05301842**: (EMERALD-3) Estudo de fase III, randomizado, aberto,
comparando TACE com durvalumab, tremelimumab e lenvatinib versus TACE
isolado em pacientes com carcinoma hepatocelular locorregional.

Patrocinador do Estudo: AstraZeneca

- [**CNI**: Research Site 20231-050, Rio de Janeiro,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05301842&location_id=RESEARCHSITERIODEJANEIRO20231050BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2020231-050%2C%20Rio%20de%20Janeiro%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">DF: 71681-603, Brasília</span>
- <span style="color: darkgray">ES: 29043-260, Vitória</span>
- <span style="color: darkgray">RJ: 24020-096, Niterói</span>
- <span style="color: darkgray">RS: 97015-450, Santa Maria</span>
- <span style="color: darkgray">RS: 91350-200, Porto Alegre</span>
- <span style="color: darkgray">SP: 09060-650, Santo André</span>
- <span style="color: darkgray">SP: 04014-002, São Paulo</span>
- <span style="color: darkgray">SP: 14784-400, Barretos</span>

**NCT05687266**: (AVANZAR) Estudo global de Fase III comparando
Datopotamab Deruxtecan com durvalumab e carboplatina versus
pembrolizumabe com quimioterapia à base de platina no tratamento de
primeira linha de NSCLC avançado sem alterações genômicas.

Patrocinador do Estudo: AstraZeneca

- <span style="color: darkgray">CE: 60335-480, Fortaleza</span>
- [**CNI**: Research Site 09323-900, Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05687266&location_id=RESEARCHSITESAOPAULO09323900BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2009323-900%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 01327-001, Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05687266&location_id=RESEARCHSITESAOPAULO01327001BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2001327-001%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 01509-900, Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05687266&location_id=RESEARCHSITESAOPAULO01509900BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2001509-900%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">ES: 29043-260, Vitória</span>
- <span style="color: darkgray">PR: 86015-520, Londrina</span>
- <span style="color: darkgray">RS: 90035-903, Porto Alegre</span>
- <span style="color: darkgray">SC: 89010-340, Blumenau</span>
- <span style="color: darkgray">SC: 88034-000, Florianópolis</span>
- <span style="color: darkgray">SP: 12030-200, Taubaté</span>
- <span style="color: darkgray">SP: 01246-000, São Paulo</span>

**NCT05774951**: (CAMBRIA-1) Estudo de fase III aberto comparando
camizestrant à terapia endócrina padrão em pacientes com câncer de mama
precoce ER+/HER2- com risco intermediário/alto de recidiva pós-terapia
locorregional.

Patrocinador do Estudo: AstraZeneca

- <span style="color: darkgray">BA: 41253-190, Salvador</span>
- <span style="color: darkgray">CE: 60430-230, Fortaleza</span>
- <span style="color: darkgray">CE: 60170-170, Fortaleza</span>
- [**CNI**: Research Site 14051-140, Ribeirão Preto,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05774951&location_id=RESEARCHSITERIBEIRAOPRETO14051140BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2014051-140%2C%20Ribeir%C3%A3o%20Preto%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 22290-160, Rio De Janeiro,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05774951&location_id=RESEARCHSITERIODEJANEIRO22290160BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2022290-160%2C%20Rio%20De%20Janeiro%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 01509-900, Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05774951&location_id=RESEARCHSITESAOPAULO01509900BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2001509-900%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 40110-060, Salvador,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05774951&location_id=RESEARCHSITESALVADOR40110060BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2040110-060%2C%20Salvador%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">DF: 70390-140, Brasília</span>
- <span style="color: darkgray">DF: 71681-603, Brasília</span>
- <span style="color: darkgray">ES: 29055-450, Vitória</span>
- <span style="color: darkgray">MG: 30150-221, Belo Horizonte</span>
- <span style="color: darkgray">MG: 37130-087, Alfenas</span>
- <span style="color: darkgray">MG: 37554-216, Pouso Alegre</span>
- <span style="color: darkgray">MG: 30130-100, Belo Horizonte</span>
- <span style="color: darkgray">MS: 79601-001, Três Lagoas</span>
- <span style="color: darkgray">MT: 78040-400, Cuiabá</span>
- <span style="color: darkgray">PE: 50070-030, Recife</span>
- <span style="color: darkgray">PR: 80810-050, Curitiba</span>
- <span style="color: darkgray">PR: 86015-520, Londrina</span>
- <span style="color: darkgray">PR: 81520-060, Curitiba</span>
- <span style="color: darkgray">RJ: 24020-096, Niterói</span>
- <span style="color: darkgray">RJ: 22250-905, Rio de Janeiro</span>
- <span style="color: darkgray">RJ: 20560-121, Rio de Janeiro</span>
- <span style="color: darkgray">RN: 59062-000, Natal</span>
- <span style="color: darkgray">RS: 90035-007, Porto Alegre</span>
- <span style="color: darkgray">RS: 90610-000, Porto Alegre</span>
- <span style="color: darkgray">RS: 90035-903, Porto Alegre</span>
- <span style="color: darkgray">RS: 95900-010, Lajeado</span>
- <span style="color: darkgray">RS: 90050-170, Porto Alegre</span>
- <span style="color: darkgray">RS: 90880-481, Porto Alegre</span>
- <span style="color: darkgray">SC: 89812-210, Chapecó</span>
- <span style="color: darkgray">SP: 01508-010, São Paulo</span>
- <span style="color: darkgray">SP: 13419-155, Piracicaba</span>
- <span style="color: darkgray">SP: 12030-200, Taubaté</span>
- <span style="color: darkgray">SP: 14784-400, Barretos</span>
- <span style="color: darkgray">SP: 01246-000, São Paulo</span>
- <span style="color: darkgray">SP: 03102-002, São Paulo</span>
- <span style="color: darkgray">SP: 08270-070, São Paulo</span>
- <span style="color: darkgray">SP: 01236-030, São Paulo</span>
- <span style="color: darkgray">SP: 01321-001, São Paulo</span>
- <span style="color: darkgray">SP: 01321-001, São Paulo</span>
- <span style="color: darkgray">SP: 01317-000, São Paulo</span>

**NCT05952557**: (CAMBRIA-2) Estudo de fase III aberto comparando
camizestrant à terapia endócrina padrão em pacientes com câncer de mama
precoce ER+/HER2- com risco intermediário-alto ou alto de recidiva após
tratamento locorregional.

Patrocinador do Estudo: AstraZeneca

- <span style="color: darkgray">BA: 40170-110, Salvador</span>
- <span style="color: darkgray">CE: 60135-237, Fortaleza</span>
- <span style="color: darkgray">CE: 60430-230, Fortaleza</span>
- [**CNI**: Research Site 74000-000, Goiânia,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05952557&location_id=RESEARCHSITEGOIANIA74000000BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2074000-000%2C%20Goi%C3%A2nia%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 71615-907, Brasília,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05952557&location_id=RESEARCHSITEBRASILIA71615907BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2071615-907%2C%20Bras%C3%ADlia%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 01327-001, Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05952557&location_id=RESEARCHSITESAOPAULO01327001BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2001327-001%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">ES: 29043-260, Vitória</span>
- <span style="color: darkgray">MG: 37130-087, Alfenas</span>
- <span style="color: darkgray">MG: 30130-100, Belo Horizonte</span>
- <span style="color: darkgray">MG: 37554-216, Pouso Alegre</span>
- <span style="color: darkgray">MS: 79601-001, Três Lagoas</span>
- <span style="color: darkgray">PB: 58015-170, João Pessoa</span>
- <span style="color: darkgray">PE: 50070-490, Recife</span>
- <span style="color: darkgray">PI: 64049-200, Teresina</span>
- <span style="color: darkgray">PR: 80810-050, Curitiba</span>
- <span style="color: darkgray">PR: 80730-380, Curitiba</span>
- <span style="color: darkgray">RJ: 22793-080, Rio de Janeiro</span>
- <span style="color: darkgray">RJ: 20560-121, Rio de Janeiro</span>
- <span style="color: darkgray">RN: 59062-000, Natal</span>
- <span style="color: darkgray">RO: 76834-899, Porto Velho</span>
- <span style="color: darkgray">RS: 90050-170, Porto Alegre</span>
- <span style="color: darkgray">RS: 90610-000, Porto Alegre</span>
- <span style="color: darkgray">RS: 90035-007, Porto Alegre</span>
- <span style="color: darkgray">SC: 89010-340, Blumenau</span>
- <span style="color: darkgray">SC: 88301-220, Itajaí</span>
- <span style="color: darkgray">SP: 03102-002, São Paulo</span>
- <span style="color: darkgray">SP: 09060-650, Santo André</span>
- <span style="color: darkgray">SP: 12030-200, Taubaté</span>
- <span style="color: darkgray">SP: 01246-000, São Paulo</span>
- <span style="color: darkgray">SP: 14015-010, Ribeirão Preto</span>
- <span style="color: darkgray">SP: 01409-002, São Paulo</span>

**NCT06079671**: (eVOLVE-Cervical) Estudo de fase III, randomizado,
duplo-cego, controlado por placebo de volrustomig em mulheres com câncer
cervical localmente avançado de alto risco após quimiorradiação à base
de platina.

Patrocinador do Estudo: AstraZeneca

- <span style="color: darkgray">BA: 40050-410, Salvador</span>
- <span style="color: darkgray">CE: 60335-480, Fortaleza</span>
- [**CNI**: Research Site 20231-050, Rio de Janeiro,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06079671&location_id=RESEARCHSITERIODEJANEIRO20231050BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2020231-050%2C%20Rio%20de%20Janeiro%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">MG: 30130-100, Belo Horizonte</span>
- <span style="color: darkgray">PI: 64049-200, Teresina</span>
- <span style="color: darkgray">PR: 80730-150, Curitiba</span>
- <span style="color: darkgray">RO: 76834-899, Porto Velho</span>
- <span style="color: darkgray">RS: 90610-000, Porto Alegre</span>
- <span style="color: darkgray">RS: 90110-270, Porto Alegre</span>
- <span style="color: darkgray">SP: 01323-001, São Paulo</span>
- <span style="color: darkgray">SP: 14784-400, Barretos</span>
- <span style="color: darkgray">SP: 01246-000, São Paulo</span>

**NCT06103864**: (TROPION-Breast05) Estudo de Fase III comparando
Dato-DXd com/sem durvalumabe versus quimioterapia mais pembrolizumabe em
pacientes com câncer de mama triplo-negativo metastático PD-L1 positivo.

Patrocinador do Estudo: AstraZeneca

- [**CNI**: Research Site 74000-000, Goiânia,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06103864&location_id=RESEARCHSITEGOIANIA74000000BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2074000-000%2C%20Goi%C3%A2nia%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">PE: 52010-075, Recife</span>
- <span style="color: darkgray">PI: 64049-200, Teresina</span>
- <span style="color: darkgray">PR: 80730-150, Curitiba</span>
- <span style="color: darkgray">RS: 90035-007, Porto Alegre</span>
- <span style="color: darkgray">SC: 88034-000, Florianópolis</span>
- <span style="color: darkgray">SC: 88301-220, Itajaí</span>
- <span style="color: darkgray">SP: 01317-000, São Paulo</span>
- <span style="color: darkgray">SP: 14784-400, Barretos</span>
- <span style="color: darkgray">SP: 01246-000, São Paulo</span>

**NCT06109779**: (ARTEMIDE-Biliary01) Estudo global de Fase III
avaliando rilvegostomig com quimioterapia versus placebo como tratamento
adjuvante pós-reseção em pacientes com câncer de vias biliares.

Patrocinador do Estudo: AstraZeneca

- [**CNI**: Research Site 01327-001, Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06109779&location_id=RESEARCHSITESAOPAULO01327001BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2001327-001%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">ES: 29043-260, Vitória</span>
- <span style="color: darkgray">RN: 59062-000, Natal</span>
- <span style="color: darkgray">RS: 91350-200, Porto Alegre</span>
- <span style="color: darkgray">RS: 97015-450, Santa Maria</span>
- <span style="color: darkgray">RS: 90035-007, Porto Alegre</span>
- <span style="color: darkgray">SP: 09060-870, Santo André</span>
- <span style="color: darkgray">SP: 01246-000, São Paulo</span>

**NCT06112379**: (TROPION-Breast04) Estudo de Fase III comparando
Dato-DXd neoadjuvante mais durvalumab versus pembrolizumab mais
quimioterapia em pacientes com câncer de mama TNBC ou receptor hormonal
baixo/HER2-negativo não tratados.

Patrocinador do Estudo: AstraZeneca

- <span style="color: darkgray">CE: 60335-480, Fortaleza</span>
- [**CNI**: Research Site 14051-140, Ribeirão Preto,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06112379&location_id=RESEARCHSITERIBEIRAOPRETO14051140BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2014051-140%2C%20Ribeir%C3%A3o%20Preto%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">DF: 71681-603, Brasília</span>
- <span style="color: darkgray">ES: 29043-260, Vitória</span>
- <span style="color: darkgray">PR: 86015-520, Londrina</span>
- <span style="color: darkgray">PR: 80440-220, Curitiba</span>
- <span style="color: darkgray">RN: 59062-000, Natal</span>
- <span style="color: darkgray">RS: 90035-007, Porto Alegre</span>
- <span style="color: darkgray">RS: 90035-903, Porto Alegre</span>
- <span style="color: darkgray">SP: 09060-650, Santo André</span>
- <span style="color: darkgray">SP: 01246-000, São Paulo</span>
- <span style="color: darkgray">SP: 12030-200, Taubaté</span>

**NCT06120491**: (EvoPAR-Prostate01) Estudo de fase III, randomizado e
duplo-cego, avaliando Saruparib (AZD5305) com agentes hormonais versus
placebo em câncer de próstata metastático sensível à castração HRRm e
não-HRRm.

Patrocinador do Estudo: AstraZeneca

- [**CNI**: Research Site 41950-640, Salvador,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06120491&location_id=RESEARCHSITESALVADOR41950640BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2041950-640%2C%20Salvador%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">MA: 65060-645, São Luís</span>
- <span style="color: darkgray">PR: 80810-050, Curitiba</span>
- <span style="color: darkgray">RJ: 22775-001, Rio de Janeiro</span>
- <span style="color: darkgray">RS: 91350-200, Porto Alegre</span>
- <span style="color: darkgray">RS: 96020-080, Pelotas</span>
- <span style="color: darkgray">RS: 90035-007, Porto Alegre</span>
- <span style="color: darkgray">SP: 01246-000, São Paulo</span>
- <span style="color: darkgray">SP: 05652-900, São Paulo</span>
- <span style="color: darkgray">SP: 01323-020, São Paulo</span>

**NCT06129864**: (eVOLVE-HNSCC) Estudo de fase III randomizado
comparando volrustomig à observação em pacientes com carcinoma
espinocelular de cabeça e pescoço localmente avançado não ressecado após
quimiorradioterapia concomitante.

Patrocinador do Estudo: AstraZeneca

- <span style="color: darkgray">CE: 60335-480, Fortaleza</span>
- [**CNI**: Research Site 14051-140, Ribeirão Preto,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06129864&location_id=RESEARCHSITERIBEIRAOPRETO14051140BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2014051-140%2C%20Ribeir%C3%A3o%20Preto%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 01509-900, Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06129864&location_id=RESEARCHSITESAOPAULO01509900BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2001509-900%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 20231-050, Rio de Janeiro,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06129864&location_id=RESEARCHSITERIODEJANEIRO20231050BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2020231-050%2C%20Rio%20de%20Janeiro%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">MG: 35162-761, Ipatinga</span>
- <span style="color: darkgray">PI: 64049-200, Teresina</span>
- <span style="color: darkgray">PR: 86015-520, Londrina</span>
- <span style="color: darkgray">RS: 91350-200, Porto Alegre</span>
- <span style="color: darkgray">RS: 98700-000, Ijuí</span>
- <span style="color: darkgray">SC: 88034-000, Florianópolis</span>
- <span style="color: darkgray">SP: 14784-400, Barretos</span>
- <span style="color: darkgray">SP: 04538-132, São Paulo</span>

**NCT06357533**: (TROPION-Lung10) Estudo global de Fase III comparando
Dato-DXd com rilvegostomig ou rilvegostomig isolado versus pembrolizumab
no tratamento de primeira linha de NSCLC não escamoso avançado com alta
PD-L1.

Patrocinador do Estudo: AstraZeneca

- [**CNI**: Research Site 22211-230, Rio de Janeiro,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06357533&location_id=RESEARCHSITERIODEJANEIRO22211230BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2022211-230%2C%20Rio%20de%20Janeiro%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">MG: 35162-761, Ipatinga</span>
- <span style="color: darkgray">PR: 80730-150, Curitiba</span>
- <span style="color: darkgray">RN: 59062-000, Natal</span>
- <span style="color: darkgray">RS: 91350-200, Porto Alegre</span>
- <span style="color: darkgray">RS: 97015-450, Santa Maria</span>
- <span style="color: darkgray">SC: 88034-000, Florianópolis</span>
- <span style="color: darkgray">SP: 14784-400, Barretos</span>
- <span style="color: darkgray">SP: 12030-200, Taubaté</span>
- <span style="color: darkgray">SP: 01221-020, São Paulo</span>

**NCT06380751**: (EvoPAR-Breast01) Estudo de fase III randomizado
comparando saruparib mais camizestrant versus inibidor de CDK4/6 mais
terapia endócrina em câncer de mama avançado com mutações BRCA1/2 ou
PALB2, HR-positivo, HER2-negativo.

Patrocinador do Estudo: AstraZeneca

- <span style="color: darkgray">BA: 41253-190, Salvador</span>
- <span style="color: darkgray">CE: 60335-480, Fortaleza</span>
- [**CNI**: Research Site 74000-000, Goiânia,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06380751&location_id=RESEARCHSITEGOIANIA74000000BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2074000-000%2C%20Goi%C3%A2nia%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 01509-900, Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06380751&location_id=RESEARCHSITESAOPAULO01509900BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2001509-900%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">ES: 29308-014, Cachoeiro de
  Itapemirim</span>
- <span style="color: darkgray">PR: 80060-900, Curitiba</span>
- <span style="color: darkgray">RS: 91350-200, Porto Alegre</span>
- <span style="color: darkgray">SP: 17210-070, Jaú</span>
- <span style="color: darkgray">SP: 14049-900, Ribeirão Preto</span>
- <span style="color: darkgray">SP: 03102-002, São Paulo</span>

**NCT06417814**: (TROPION-Lung15) Estudo de Fase III comparando Dato-DXd
com/sem Osimertinib à quimioterapia de platina em câncer de pulmão não
pequenas células avançado com mutação EGFR após progressão com
Osimertinib.

Patrocinador do Estudo: AstraZeneca

- [**CNI**: Research Site 01327-001, Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06417814&location_id=RESEARCHSITESAOPAULO01327001BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2001327-001%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 01323-900, São Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06417814&location_id=RESEARCHSITESAOPAULO01323900BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2001323-900%2C%20S%C3%A3o%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 90470-340, Porto Alegre,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06417814&location_id=RESEARCHSITEPORTOALEGRE90470340BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2090470-340%2C%20Porto%20Alegre%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">RJ: 22775-001, Rio de Janeiro</span>
- <span style="color: darkgray">RJ: 22281-100, Rio de Janeiro</span>
- <span style="color: darkgray">RJ: 22250-905, Rio de Janeiro</span>
- <span style="color: darkgray">RS: 90610-000, Porto Alegre</span>
- <span style="color: darkgray">SC: 88301-220, Itajaí</span>
- <span style="color: darkgray">SP: 14784-400, Barretos</span>

**NCT04379596**: (DESTINY-Gastric-03) Estudo multicêntrico de Fase 1b/2
avaliando segurança, tolerabilidade e atividade antitumoral de
Trastuzumab Deruxtecan isolado ou com quimioterapia/imunoterapia em
câncer gástrico HER2-expressante.

Patrocinador do Estudo: AstraZeneca

- [**CNI**: Research Site 14051-140, Ribeirão Preto,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT04379596&location_id=RESEARCHSITERIBEIRAOPRETO14051140BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2014051-140%2C%20Ribeir%C3%A3o%20Preto%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 045202-001, São Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT04379596&location_id=RESEARCHSITESAOPAULO045202001BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%20045202-001%2C%20S%C3%A3o%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 01509-900, Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT04379596&location_id=RESEARCHSITESAOPAULO01509900BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2001509-900%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">PR: 86015-520, Londrina</span>
- <span style="color: darkgray">RJ: 22793-080, Rio de Janeiro</span>
- <span style="color: darkgray">RN: 59062-000, Natal</span>
- <span style="color: darkgray">RS: 97015-450, Santa Maria</span>
- <span style="color: darkgray">RS: 90160-092, Porto Alegre</span>
- <span style="color: darkgray">SC: 88020-210, Florianópolis</span>
- <span style="color: darkgray">SP: 15090-000, São José do Rio
  Preto</span>
- <span style="color: darkgray">SP: 03102-002, São Paulo</span>

**NCT04482309**: (DESTINY-PanTumor02) Estudo multicêntrico de Fase 2 que
avalia a eficácia e segurança do trastuzumab deruxtecan no tratamento de
tumores HER2-expressivos selecionados em vários tipos de câncer.

Patrocinador do Estudo: AstraZeneca

- [**CNI**: Research Site 14051-140, Ribeirão Preto,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT04482309&location_id=RESEARCHSITERIBEIRAOPRETO14051140BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2014051-140%2C%20Ribeir%C3%A3o%20Preto%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">ES: 29043-260, Vitória</span>
- <span style="color: darkgray">PR: 81520-060, Curitiba</span>
- <span style="color: darkgray">RN: 59062-000, Natal</span>
- <span style="color: darkgray">RS: 90035-007, Porto Alegre</span>
- <span style="color: darkgray">RS: 90035-007, Porto Alegre</span>
- <span style="color: darkgray">RS: 91350-200, Porto Alegre</span>
- <span style="color: darkgray">SP: 01246-000, São Paulo</span>
- <span style="color: darkgray">SP: 14784-400, Barretos</span>

**NCT05952024**: (ACRUE) Estudo de Fase II que avalia a segurança,
tolerabilidade e eficácia de acalabrutinibe e rituximabe em pacientes
idosos ou frágeis não tratados com linfoma difuso de grandes células B.

Patrocinador do Estudo: AstraZeneca

- [**CNI**: Research Site 04502-001, São Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05952024&location_id=RESEARCHSITESAOPAULO04502001BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2004502-001%2C%20S%C3%A3o%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site 20231-050, Rio de Janeiro,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05952024&location_id=RESEARCHSITERIODEJANEIRO20231050BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2020231-050%2C%20Rio%20de%20Janeiro%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">DF: 70390-140, Brasília</span>
- <span style="color: darkgray">DF: 70840-901, Brasília</span>
- <span style="color: darkgray">DF: 70200-730, Brasília</span>
- <span style="color: darkgray">GO: 74605-010, Goiânia</span>
- <span style="color: darkgray">MA: 65060-645, São Luís</span>
- <span style="color: darkgray">MG: 30150-221, Belo Horizonte</span>
- <span style="color: darkgray">PE: 50070-490, Recife</span>
- <span style="color: darkgray">PR: 81520-060, Curitiba</span>
- <span style="color: darkgray">RN: 59062-000, Natal</span>
- <span style="color: darkgray">RS: 90035-007, Porto Alegre</span>
- <span style="color: darkgray">RS: 90880-481, Porto Alegre</span>
- <span style="color: darkgray">SC: 88020-210, Florianópolis</span>
- <span style="color: darkgray">SC: 88034-000, Florianópolis</span>
- <span style="color: darkgray">SP: 18030-005, Sorocaba</span>
- <span style="color: darkgray">SP: 05652-900, São Paulo</span>
- <span style="color: darkgray">SP: 14015-010, Ribeirão Preto</span>
- <span style="color: darkgray">SP: 14784-400, Barretos</span>
- <span style="color: darkgray">SP: 08270-070, São Paulo</span>
- <span style="color: darkgray">SP: 01409-002, São Paulo</span>
- <span style="color: darkgray">SP: 15090-000, São José do Rio
  Preto</span>
- <span style="color: darkgray">SP: 01227-000, São Paulo</span>
- <span style="color: darkgray">SP: 13034-685, Campinas</span>
- <span style="color: darkgray">SP: 01323-000, São Paulo</span>

**NCT06131424**: (iRetroBC) Estudo multicêntrico retrospectivo que
avalia a prevalência de HER2-baixo, características clínicas e
resultados de tratamento em pacientes com câncer de mama metastático
HER2-negativo após terapia sistêmica.

Patrocinador do Estudo: AstraZeneca

- [**CNI**: Research Site - , Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06131424&location_id=RESEARCHSITESAOPAULOBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%20%20-%20%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT06230328**: (BRA-HEP) Estudo retrospectivo multicêntrico que
analisa perfis epidemiológicos, manejo clínico e sobrevivência de
pacientes brasileiros com carcinoma hepatocelular de 2017 a 2022.

Patrocinador do Estudo: AstraZeneca

- [**CNI**: Research Site - , Salvador,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06230328&location_id=RESEARCHSITESALVADORBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%20%20-%20%2C%20Salvador%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site - , Natal,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06230328&location_id=RESEARCHSITENATALBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%20%20-%20%2C%20Natal%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site - , Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06230328&location_id=RESEARCHSITESAOPAULOBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%20%20-%20%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site - , Porto Alegre,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06230328&location_id=RESEARCHSITEPORTOALEGREBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%20%20-%20%2C%20Porto%20Alegre%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site - , Florianopolis,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06230328&location_id=RESEARCHSITEFLORIANOPOLISBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%20%20-%20%2C%20Florianopolis%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site - , Vitoria,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06230328&location_id=RESEARCHSITEVITORIABRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%20%20-%20%2C%20Vitoria%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site - , Sao Bernardo do Campo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06230328&location_id=RESEARCHSITESAOBERNARDODOCAMPOBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%20%20-%20%2C%20Sao%20Bernardo%20do%20Campo%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site - , Recife,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06230328&location_id=RESEARCHSITERECIFEBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%20%20-%20%2C%20Recife%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site - , Curitiba,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06230328&location_id=RESEARCHSITECURITIBABRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%20%20-%20%2C%20Curitiba%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site - , Belo Horizonte,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06230328&location_id=RESEARCHSITEBELOHORIZONTEBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%20%20-%20%2C%20Belo%20Horizonte%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site - , Rio de Janeiro,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06230328&location_id=RESEARCHSITERIODEJANEIROBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%20%20-%20%2C%20Rio%20de%20Janeiro%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Site - , Sao Jose do Rio Preto,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06230328&location_id=RESEARCHSITESAOJOSEDORIOPRETOBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%20%20-%20%2C%20Sao%20Jose%20do%20Rio%20Preto%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">SP: 14784-400, Barretos</span>

**NCT06491862**: (RACE-2L) Estudo retrospectivo revisando prontuários
médicos no Brasil para avaliar desfechos em pacientes com NSCLC não
escamoso após falha de quimioterapia à base de platina de 2017 a 2022.

Patrocinador do Estudo: AstraZeneca

- [**CNI**: Research Site 01333-010, Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06491862&location_id=RESEARCHSITESAOPAULO01333010BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Site%2001333-010%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">RN: 59062-000, Natal</span>
- <span style="color: darkgray">SP: 05652-900, São Paulo</span>
- <span style="color: darkgray">SP: 01323-020, São Paulo</span>
- <span style="color: darkgray">SP: 01308-050, São Paulo</span>

**NCT04142437**: (ON-TRK) Estudo observacional que avalia a eficácia e
tolerância do Larotrectinib em pacientes adultos e pediátricos com
câncer de fusão TRK localmente avançado ou metastático por 24 a 60
meses.

Patrocinador do Estudo: Bayer

- [**CNI**: Many Locations - , Multiple Locations,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT04142437&location_id=MANYLOCATIONSMULTIPLELOCATIONSBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Many%20Locations%20%20-%20%2C%20Multiple%20Locations%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT06117891**: (REFINE-IO) Estudo observacional que coleta dados sobre
a eficácia do tratamento em adultos com carcinoma hepatocelular
irressecável após atezolizumabe mais bevacizumabe ou outras combinações
1L-IO.

Patrocinador do Estudo: Bayer

- [**CNI**: Many Locations - , Multiple Locations,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06117891&location_id=MANYLOCATIONSMULTIPLELOCATIONSBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Many%20Locations%20%20-%20%2C%20Multiple%20Locations%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT04810078**: (CheckMate-67T) Estudo de fase 3 comparando Nivolumab
subcutâneo vs. intravenoso em pacientes com carcinoma de células renais
claras avançado após terapia sistêmica.

Patrocinador do Estudo: Bristol-Myers Squibb

- [**CNI**: Local Institution - 0096 01327-0001, Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT04810078&location_id=LOCALINSTITUTION0096SAOPAULO013270001BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Local%20Institution%20-%200096%2001327-0001%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">PR: 80520-174, Curitiba</span>
- <span style="color: darkgray">RJ: 20230-130, Rio de Janeiro</span>
- <span style="color: darkgray">RS: 98700-000, Ijuí</span>
- <span style="color: darkgray">RS: 91350-200, Porto Alegre</span>
- <span style="color: darkgray">RS: 98700-000, Ijuí</span>
- <span style="color: darkgray">SP: 01246-000, São Paulo</span>
- <span style="color: darkgray">SP: 14784-400, Barretos</span>
- <span style="color: darkgray">SP: 15090-000, São José do Rio
  Preto</span>
- <span style="color: darkgray">SP: 01308-050, São Paulo</span>

**NCT05827016**: (EXCALIBER-Maintenance) Estudo de fase 3 randomizado
comparando iberdomide vs. lenalidomide como manutenção pós-ASCT em
pacientes com mieloma múltiplo recém-diagnosticado.

Patrocinador do Estudo: Bristol-Myers Squibb

- <span style="color: darkgray">BA: 40110-150, Salvador</span>
- [**CNI**: Local Institution - 0096 21941-913, Rio de Janeiro,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05827016&location_id=LOCALINSTITUTION0096RIODEJANEIRO21941913BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Local%20Institution%20-%200096%2021941-913%2C%20Rio%20de%20Janeiro%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">PR: 80520-174, Curitiba</span>
- <span style="color: darkgray">RJ: 20230-130, Rio de Janeiro</span>
- <span style="color: darkgray">RJ: 24020-096, Niterói</span>
- <span style="color: darkgray">RS: 90880-481, Porto Alegre</span>
- <span style="color: darkgray">SP: 05403-010, São Paulo</span>
- <span style="color: darkgray">SP: 14015-010, Ribeirão Preto</span>
- <span style="color: darkgray">SP: 04537-081, São Paulo</span>
- <span style="color: darkgray">SP: 14784-400, Barretos</span>
- <span style="color: darkgray">SP: 08270-070, São Paulo</span>

**NCT03899155**: Estudo observacional de longo prazo avaliando a
segurança do nivolumab e outras terapias contra o câncer em pacientes de
ensaios BMS em vários tipos de tumor.

Patrocinador do Estudo: Bristol-Myers Squibb

- [**CNI**: Local Institution - 0355 01327-001, Sao Paulo,
  SP](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT03899155&location_id=LOCALINSTITUTION0355SAOPAULOSP01327001BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Local%20Institution%20-%200355%2001327-001%2C%20Sao%20Paulo%2C%20SP&form_type=Identificar%20Centro)
- <span style="color: darkgray">MG: 30130-090, Belo Horizonte</span>
- <span style="color: darkgray">RJ: 22793-080, Rio de Janeiro</span>
- <span style="color: darkgray">RJ: 20220-430, Rio de Janeiro</span>
- <span style="color: darkgray">RS: 90050-170, Porto Alegre</span>
- <span style="color: darkgray">RS: 98700-000, Ijuí</span>
- <span style="color: darkgray">RS: 90610-000, Porto Alegre</span>
- <span style="color: darkgray">RS: 90035-903, Porto Alegre</span>
- <span style="color: darkgray">SP: 15090-000, São José do Rio
  Preto</span>
- <span style="color: darkgray">SP: 01246-000, São Paulo</span>
- <span style="color: darkgray">SP: 14784-400, Barretos</span>
- <span style="color: darkgray">SP: 01308-060, São Paulo</span>
- <span style="color: darkgray">SP: 01308-050, São Paulo</span>

**NCT05501886**: (VIKTORIA-1) Estudo de fase 3, aberto, comparando
gedatolisib com fulvestranto, com/sem palbociclibe, a terapias padrão em
câncer de mama avançado HR+/HER2- após tratamento com inibidor de
CDK4/6.

Patrocinador do Estudo: Celcuity Inc

- <span style="color: darkgray">BA: 41810-011, Salvador</span>
- <span style="color: darkgray">CE: 60810-180, Fortaleza</span>
- [**CNI**: Juiz de Fora Eurolatino Research Center - , Minas Gerais,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05501886&location_id=JUIZDEFORAEUROLATINORESEARCHCENTERMINASGERAISBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Juiz%20de%20Fora%20Eurolatino%20Research%20Center%20%20-%20%2C%20Minas%20Gerais%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">PA: 66063-495, Belém</span>
- <span style="color: darkgray">RS: 98700-000, Ijuí</span>
- <span style="color: darkgray">SP: 01401-002, São Paulo</span>
- <span style="color: darkgray">SP: 01525-001, São Paulo</span>

**NCT05668988**: Estudo de Fase 3 comparando DZD9008 com quimioterapia à
base de platina como tratamento de primeira linha para NSCLC avançado
com mutação de inserção no Exon 20 do EGFR.

Patrocinador do Estudo: Dizal Pharmaceuticals

- [**CNI**: WK28 Investigative Site - , São Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05668988&location_id=WK28INVESTIGATIVESITESAOPAULOBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20WK28%20Investigative%20Site%20%20-%20%2C%20S%C3%A3o%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: WK28 Investigative Site - , Cachoeiro De Itapemirim,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05668988&location_id=WK28INVESTIGATIVESITECACHOEIRODEITAPEMIRIMBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20WK28%20Investigative%20Site%20%20-%20%2C%20Cachoeiro%20De%20Itapemirim%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: WK28 Investigative Site - , Recife,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05668988&location_id=WK28INVESTIGATIVESITERECIFEBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20WK28%20Investigative%20Site%20%20-%20%2C%20Recife%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: WK28 Investigative Site - , Rio De Janeiro,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05668988&location_id=WK28INVESTIGATIVESITERIODEJANEIROBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20WK28%20Investigative%20Site%20%20-%20%2C%20Rio%20De%20Janeiro%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: WK28 Investigative Site - , Porto Alegre,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05668988&location_id=WK28INVESTIGATIVESITEPORTOALEGREBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20WK28%20Investigative%20Site%20%20-%20%2C%20Porto%20Alegre%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: WK28 Investigative Site - , Natal,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05668988&location_id=WK28INVESTIGATIVESITENATALBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20WK28%20Investigative%20Site%20%20-%20%2C%20Natal%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">SP: 14784-400, Barretos</span>

**NCT05514054**: (EMBER-4) Estudo de fase 3 randomizado comparando
Imlunestrant adjuvante à terapia endócrina padrão em pacientes com
câncer de mama precoce ER+, HER2- com alto risco de recidiva após 2-5
anos de terapia prévia.

Patrocinador do Estudo: Eli Lilly and Company

- <span style="color: darkgray">BA: 40170-110, Salvador</span>
- <span style="color: darkgray">CE: 60430-230, Fortaleza</span>
- [**CNI**: Oncocentro de Minas Gerais 30180-060, Belo Horizonte, Minas
  Gera](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05514054&location_id=ONCOCENTRODEMINASGERAISBELOHORIZONTEMINASGERA30180060BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Oncocentro%20de%20Minas%20Gerais%2030180-060%2C%20Belo%20Horizonte%2C%20Minas%20Gera&form_type=Identificar%20Centro)
- <span style="color: darkgray">DF: 70200-730, Brasília</span>
- <span style="color: darkgray">ES: 29055-450, Vitória</span>
- <span style="color: darkgray">GO: 74605-070, Goiânia</span>
- <span style="color: darkgray">PA: 66063-495, Belém</span>
- <span style="color: darkgray">PE: 50070-170, Recife</span>
- <span style="color: darkgray">PR: 80810-050, Curitiba</span>
- <span style="color: darkgray">PR: 86015-520, Londrina</span>
- <span style="color: darkgray">RJ: 22061-080, Rio de Janeiro</span>
- <span style="color: darkgray">RJ: 20560-121, Rio de Janeiro</span>
- <span style="color: darkgray">RJ: 22250-905, Rio de Janeiro</span>
- <span style="color: darkgray">RJ: 22775-001, Rio de Janeiro</span>
- <span style="color: darkgray">RO: 76834-899, Porto Velho</span>
- <span style="color: darkgray">RS: 90110-270, Porto Alegre</span>
- <span style="color: darkgray">RS: 98700-000, Ijuí</span>
- <span style="color: darkgray">RS: 90560-032, Porto Alegre</span>
- <span style="color: darkgray">RS: 90610-001, Porto Alegre</span>
- <span style="color: darkgray">SP: 14780-360, Barretos</span>
- <span style="color: darkgray">SP: 04556-100, São Paulo</span>
- <span style="color: darkgray">SP: 01323-020, São Paulo</span>
- <span style="color: darkgray">SP: 14015-010, Ribeirão Preto</span>
- <span style="color: darkgray">SP: 09060-870, Santo André</span>
- <span style="color: darkgray">SP: 01308-060, São Paulo</span>
- <span style="color: darkgray">SP: 01323-001, São Paulo</span>
- <span style="color: darkgray">SP: 01509-010, São Paulo</span>
- <span style="color: darkgray">SP: 01401-002, São Paulo</span>
- <span style="color: darkgray">SP: 15090-000, São José do Rio
  Preto</span>
- <span style="color: darkgray">SP: 01223-001, São Paulo</span>
- <span style="color: darkgray">SP: 01227-000, São Paulo</span>
- <span style="color: darkgray">SP: 01236-030, São Paulo</span>
- <span style="color: darkgray">SP: 01246-000, São Paulo</span>
- <span style="color: darkgray">SP: 01317-000, São Paulo</span>
- <span style="color: darkgray">SP: 04014-002, São Paulo</span>
- <span style="color: darkgray">SP: 04039-000, São Paulo</span>

**NCT06472076**: (GALAXIES Lung-301) Estudo de fase 3, randomizado e
duplo-cego, comparando belrestotug mais dostarlimab versus pembrolizumab
mais placebo em pacientes com NSCLC PD-L1 alto, não ressecável e
avançado não tratados.

Patrocinador do Estudo: GlaxoSmithKline

- <span style="color: darkgray">BA: 40415-006, Salvador</span>
- [**CNI**: GSK Investigational Site 60336-232, Fortaleza,
  Ceará](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06472076&location_id=GSKINVESTIGATIONALSITEFORTALEZACEARA60336232BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20GSK%20Investigational%20Site%2060336-232%2C%20Fortaleza%2C%20Cear%C3%A1&form_type=Identificar%20Centro)
- <span style="color: darkgray">ES: 29043-260, Vitória</span>
- <span style="color: darkgray">PA: 66073-000, Belém</span>
- <span style="color: darkgray">PR: 80810-050, Curitiba</span>
- <span style="color: darkgray">PR: 86015-520, Londrina</span>
- <span style="color: darkgray">RO: 76834-899, Porto Velho</span>
- <span style="color: darkgray">SC: 88034-000, Florianópolis</span>
- <span style="color: darkgray">SP: 15090-000, São José do Rio
  Preto</span>
- <span style="color: darkgray">SP: 14780-360, Barretos</span>
- <span style="color: darkgray">SP: 01246-903, Pacaembu</span>

**NCT05646862**: (INAVO121) Estudo multicêntrico fase III randomizado
comparando eficácia e segurança de Inavolisib mais Fulvestrant versus
Alpelisib mais Fulvestrant em câncer de mama HR-positivo, HER2-negativo,
PIK3CA-mutado.

Patrocinador do Estudo: Hoffmann-La Roche

- <span style="color: darkgray">BA: 41810-011, Salvador</span>
- [**CNI**: NUPEC 30220-140, Belo Horizonte,
  MG](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05646862&location_id=NUPECBELOHORIZONTEMG30220140BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20NUPEC%2030220-140%2C%20Belo%20Horizonte%2C%20MG&form_type=Identificar%20Centro)
- <span style="color: darkgray">DF: 70390-140, Brasília</span>
- <span style="color: darkgray">PE: 50070-490, Recife</span>
- <span style="color: darkgray">PE: 50040-000, Recife</span>
- <span style="color: darkgray">PI: 64049-200, Teresina</span>
- <span style="color: darkgray">PR: 80440-220, Curitiba</span>
- <span style="color: darkgray">RJ: 22281-100, Rio de Janeiro</span>
- <span style="color: darkgray">RN: 59062-000, Natal</span>
- <span style="color: darkgray">RS: 90610-001, Porto Alegre</span>
- <span style="color: darkgray">RS: 90020-090, Porto Alegre</span>
- <span style="color: darkgray">SP: 15090-000, São José do Rio
  Preto</span>
- <span style="color: darkgray">SP: 01308-050, São Paulo</span>

**NCT04262466**: Estudo de Fase 1/2 que avalia a segurança e eficácia do
brenetafusp (IMC-F106C) em pacientes adultos com cânceres
PRAME-positivos e marcador tecidual HLA-A2.

Patrocinador do Estudo: Immunocore Ltd

- [**CNI**: National Cancer Institute - , Rio De Janeiro,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT04262466&location_id=NATIONALCANCERINSTITUTERIODEJANEIROBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20National%20Cancer%20Institute%20%20-%20%2C%20Rio%20De%20Janeiro%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: D’Or Institute for Research and Education - , Rio de
  Janeiro,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT04262466&location_id=DORINSTITUTEFORRESEARCHANDEDUCATIONRIODEJANEIROBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20D%27Or%20Institute%20for%20Research%20and%20Education%20%20-%20%2C%20Rio%20de%20Janeiro%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">RS: 91350-200, Porto Alegre</span>
- <span style="color: darkgray">SP: 05652-900, São Paulo</span>

**NCT06345729**: (MK-1084) Estudo de fase 3, randomizado e duplo-cego
comparando MK-1084 com pembrolizumab versus pembrolizumab mais placebo
no tratamento inicial de NSCLC metastático com mutação KRAS G12C e PD-L1
TPS ≥50%.

Patrocinador do Estudo: Merck Sharp & Dohme LLC

- [**CNI**: Americas ( Site 0431) 22775-001, Rio de Janeiro,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06345729&location_id=AMERICASSITE0431RIODEJANEIRO22775001BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Americas%20%28%20Site%200431%29%2022775-001%2C%20Rio%20de%20Janeiro%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Hospital de Câncer de Recife ( Site 0447) 50040-000, Recife,
  Pernambuco](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06345729&location_id=HOSPITALDECANCERDERECIFESITE0447RECIFEPERNAMBUCO50040000BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Hospital%20de%20C%C3%A2ncer%20de%20Recife%20%28%20Site%200447%29%2050040-000%2C%20Recife%2C%20Pernambuco&form_type=Identificar%20Centro)
- <span style="color: darkgray">PI: 64049-200, Teresina</span>
- <span style="color: darkgray">RN: 59062-000, Natal</span>

**NCT04613596**: Estudo de Fase 2/3 avaliando adagrasib isolado e com
pembrolizumab versus pembrolizumab em pacientes com NSCLC avançado com
mutação KRAS G12C.

Patrocinador do Estudo: Mirati Therapeutics Inc.

- [**CNI**: Local Institution - Unk003 20231-050, Rio de Janeiro,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT04613596&location_id=LOCALINSTITUTIONUNK003RIODEJANEIRO20231050BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Local%20Institution%20-%20Unk003%2020231-050%2C%20Rio%20de%20Janeiro%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">RS: 90610-000, Porto Alegre</span>
- <span style="color: darkgray">RS: 98700-000, Ijuí</span>
- <span style="color: darkgray">RS: 95900-010, Lajeado</span>
- <span style="color: darkgray">SP: 15090-000, São José do Rio
  Preto</span>
- <span style="color: darkgray">SP: 01246-000, São Paulo</span>
- <span style="color: darkgray">SP: 14784-400, Barretos</span>

**NCT05853575**: Estudo randomizado comparando dois regimes de dosagem
de adagrasib em pacientes previamente tratados com NSCLC com mutação
KRAS G12C.

Patrocinador do Estudo: Mirati Therapeutics Inc.

- [**CNI**: Local Institution - 181 41950-610, Salvador,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05853575&location_id=LOCALINSTITUTION181SALVADOR41950610BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Local%20Institution%20-%20181%2041950-610%2C%20Salvador%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">ES: 29308-020, Cachoeiro de
  Itapemirim</span>
- <span style="color: darkgray">MG: 30360-680, Belo Horizonte</span>
- <span style="color: darkgray">RS: 90610-000, Porto Alegre</span>
- <span style="color: darkgray">SC: 88301-220, Itajaí</span>
- <span style="color: darkgray">SP: 01509-010, São Paulo</span>

**NCT05161195**: Estudo aberto, multicêntrico de extensão avaliando a
segurança a longo prazo do ribociclib com outros medicamentos para
pacientes em estudo global da Novartis que se beneficiam do tratamento
contínuo.

Patrocinador do Estudo: Novartis Pharmaceuticals

- [**CNI**: Novartis Investigative Site 01255-000, Sao Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05161195&location_id=NOVARTISINVESTIGATIVESITESAOPAULO01255000BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Novartis%20Investigative%20Site%2001255-000%2C%20Sao%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- <span style="color: darkgray">RN: 59062-000, Natal</span>
- <span style="color: darkgray">RS: 98700-000, Ijuí</span>
- <span style="color: darkgray">SC: 88034-000, Florianópolis</span>
- <span style="color: darkgray">SP: 15090-000, São José do Rio
  Preto</span>
- <span style="color: darkgray">SP: 03102-002, São Paulo</span>
- <span style="color: darkgray">SP: 01317-000, São Paulo</span>

**NCT05541341**: Estudo de registro prospectivo que avalia a eficácia e
segurança do Tisagenlecleucel em pacientes brasileiros com malignidades
de linfócitos B ao longo de 15 anos em três coortes.

Patrocinador do Estudo: Novartis Pharmaceuticals

- [**CNI**: Novartis Investigative Site 34006-059, Minas Gerais, Belo
  Horizonte](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05541341&location_id=NOVARTISINVESTIGATIVESITEMINASGERAISBELOHORIZONTE34006059BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Novartis%20Investigative%20Site%2034006-059%2C%20Minas%20Gerais%2C%20Belo%20Horizonte&form_type=Identificar%20Centro)
- [**CNI**: Novartis Investigative Site 04544-000, Sao Paulo,
  SP](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05541341&location_id=NOVARTISINVESTIGATIVESITESAOPAULOSP04544000BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Novartis%20Investigative%20Site%2004544-000%2C%20Sao%20Paulo%2C%20SP&form_type=Identificar%20Centro)
- <span style="color: darkgray">PR: 81520-060, Curitiba</span>
- <span style="color: darkgray">SP: 01509-010, São Paulo</span>
- <span style="color: darkgray">SP: 01409-002, São Paulo</span>
- <span style="color: darkgray">SP: 01323-020, São Paulo</span>

**NCT05477576**: (ACTION-1) Estudo de fase 1b/3 comparando RYZ101 com
tratamento padrão em pacientes com GEP-NETs avançados, inoperáveis,
SSTR+ após terapia com 177Lu-SSA.

Patrocinador do Estudo: RayzeBio, Inc.

- [**CNI**: Research Facility - , Brasília,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05477576&location_id=RESEARCHFACILITYBRASILIABRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Facility%20%20-%20%2C%20Bras%C3%ADlia%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Facility - , São Paulo,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05477576&location_id=RESEARCHFACILITYSAOPAULOBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Facility%20%20-%20%2C%20S%C3%A3o%20Paulo%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: Research Facility - , Rio De Janeiro,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05477576&location_id=RESEARCHFACILITYRIODEJANEIROBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Research%20Facility%20%20-%20%2C%20Rio%20De%20Janeiro%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT05070858**: (NIMBLE) Estudo que avalia a eficácia e segurança da
terapia combinada de pozelimab e cemdisiran e da monoterapia com
cemdisiran em pacientes com miastenia gravis generalizada sintomática.

Patrocinador do Estudo: Regeneron Pharmaceuticals

- [**CNI**: Jordy Sinapse medicina LTDA 06655-250, Itapevi, Sao
  Paulo](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT05070858&location_id=JORDYSINAPSEMEDICINALTDAITAPEVISAOPAULO06655250BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Jordy%20Sinapse%20medicina%20LTDA%2006655-250%2C%20Itapevi%2C%20Sao%20Paulo&form_type=Identificar%20Centro)
- <span style="color: darkgray">RS: 90110-000, Porto Alegre</span>
- <span style="color: darkgray">SP: 04023-062, São Paulo</span>
- <span style="color: darkgray">SP: 05403-010, São Paulo</span>

**NCT06348199**: (SB27) Estudo de fase III, randomizado e duplo-cego,
comparando eficácia, segurança, farmacocinética e imunogenicidade do
SB27 vs. Keytruda em pacientes com NSCLC metastático não-escamoso.

Patrocinador do Estudo: Samsung Bioepis Co., Ltd.

- [**CNI**: SB Investigative Site - , Porto Alegre,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06348199&location_id=SBINVESTIGATIVESITEPORTOALEGREBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20SB%20Investigative%20Site%20%20-%20%2C%20Porto%20Alegre%2C%20%20-%20&form_type=Identificar%20Centro)
- [**CNI**: SB Investigative Site - , Florianópolis,
  -](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT06348199&location_id=SBINVESTIGATIVESITEFLORIANOPOLISBRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20SB%20Investigative%20Site%20%20-%20%2C%20Florian%C3%B3polis%2C%20%20-%20&form_type=Identificar%20Centro)

**NCT04152109**: (PICS) Avaliação do impacto do Passe Espírita na saúde
mental, física e qualidade de vida por meio de práticas integrativas no
Brasil.

Patrocinador do Estudo: Universidade Federal do Triangulo Mineiro

- [**CNI**: Núcleo de Praticas Integrativas e Complementares 381000 000,
  Uberaba, Minas
  Gerais](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT04152109&location_id=NUCLEODEPRATICASINTEGRATIVASECOMPLEMENTARESUBERABAMINASGERAIS381000000BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20N%C3%BAcleo%20de%20Praticas%20Integrativas%20e%20Complementares%20381000%20000%2C%20Uberaba%2C%20Minas%20Gerais&form_type=Identificar%20Centro)

**NCT04236700**: Estudo que avalia a prevalência de lesões orais e
periorais em trabalhadores móveis de praia expostos ao sol, investigando
associações sociodemográficas, ocupacionais e de saúde geral.

Patrocinador do Estudo: Universidade Metropolitana de Santos

- [**CNI**: Caio Vinicius Gonçalves Roman Torres 11015001, Santos,
  SP](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT04236700&location_id=CAIOVINICIUSGONCALVESROMANTORRESSANTOSSP11015001BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Caio%20Vinicius%20Gon%C3%A7alves%20Roman%20Torres%2011015001%2C%20Santos%2C%20SP&form_type=Identificar%20Centro)
- [**CNI**: Caio Torres 11045, Santos,
  SP](https://flazar.shinyapps.io/formsapp?study_nct_id=NCT04236700&location_id=CAIOTORRESSANTOSSP11045BRAZIL&location_full_name=%28Centro%20N%C3%A3o-Identificado%29%2C%20Caio%20Torres%2011045%2C%20Santos%2C%20SP&form_type=Identificar%20Centro)
